Residency · Residency · Medical Genetics Genomics

Mosaicism: Somatic, Germline, and Confined Placental

Fundamental Concepts

Definition

Mosaicism refers to the presence of two or more genetically distinct cell populations derived from a single zygote within one individual. This is distinct from chimerism, which arises from the fusion of two separate zygotes, as occurs in dizygotic twin fusion or after bone marrow transplant. Mosaicism arises from post-zygotic mutation events, meaning mutations that occur after fertilization during embryonic development or later in life.

Timing Determines Distribution

The timing of the post-zygotic mutation critically determines its distribution throughout the body. Mutations occurring at the first cell division affect approximately 50% of cells. Mutations occurring later in development affect progressively smaller cell populations. The earlier the mutation occurs, the more tissues and cell types are affected. Mutations before gastrulation (approximately day 14) can affect all three germ layers, while mutations occurring after tissue differentiation may be limited to a single organ or cell lineage.

Types of Post-Zygotic Mutations

Post-zygotic mutations encompass a wide range of genetic changes, including point mutations (single nucleotide variants), small insertions and deletions, chromosomal aneuploidy from mitotic nondisjunction or anaphase lag, structural rearrangements, copy number changes, trinucleotide repeat expansions, and epigenetic alterations such as mosaic imprinting defects.

Somatic Mosaicism

General Principles

Somatic mosaicism affects body (somatic) cells but not germline cells. The mutant population is present in a variable proportion of cells across tissues. Distribution often follows developmental lineages, such as Blaschko lines for ectodermal mosaicism. The phenotypic manifestations may be segmental or patchy. Standard genetic testing on blood may miss the variant entirely if mutant cells are absent or present at low frequency in blood.

Clinical Examples of Somatic Mosaicism

Segmental/Mosaic Overgrowth Syndromes

PIK3CA-related overgrowth spectrum (PROS) involves activating PIK3CA variants present in affected tissue but absent from blood, and encompasses conditions including CLOVES syndrome, macrodactyly, hemimegalencephaly, and fibroadipose overgrowth. Proteus syndrome, caused by the AKT1 variant, is almost exclusively mosaic because the germline form would be lethal; it manifests as progressive, asymmetric overgrowth of bone, connective tissue, and skin. Sturge-Weber syndrome is caused by a somatic mosaic GNAQ R183Q variant in endothelial cells, producing a port-wine stain, leptomeningeal angiomatosis, and glaucoma. McCune-Albright syndrome results from a mosaic activating GNAS1 R201H variant causing polyostotic fibrous dysplasia, cafe-au-lait macules, and precocious puberty.

Mosaic Chromosomal Conditions

Mosaic trisomy 21 accounts for approximately 2 to 4% of Down syndrome cases, with phenotypic severity correlating imperfectly with the proportion of trisomic cells. Mosaic Turner syndrome (45,X/46,XX) generally produces a milder phenotype than non-mosaic 45,X, and fertility may be preserved. Pallister-Killian syndrome (mosaic tetrasomy 12p) demonstrates tissue-limited mosaicism: the isochromosome 12p is found in skin fibroblasts and amniocytes but is often absent from blood lymphocytes. Mosaic trisomy 8 has a variable phenotype and is often detected in fibroblasts or bone marrow but not in lymphocytes.

Mosaic Skin Disorders

Distribution along Blaschko lines reflects patterns of clonal ectodermal migration during embryogenesis. Incontinentia pigmenti (IKBKG) is X-linked and shows a mosaic pattern in females due to X-inactivation. Epidermal nevi may be associated with mosaic RAS pathway variants in HRAS, KRAS, NRAS, or FGFR3. Segmental neurofibromatosis involves an NF1 variant present in a body segment, with the risk of germline transmission depending on whether the gonads are involved.

Detection of Somatic Mosaicism

Standard Sanger sequencing can detect mosaicism typically above 15 to 20% allele fraction. Next-generation sequencing with deep coverage (greater than 500x) can detect mosaicism below 5% allele fraction. Digital droplet PCR is highly sensitive for known variants and can detect mosaicism below 1%. Chromosomal microarray can detect mosaic aneuploidy or CNVs at approximately 15 to 20% levels. Testing the appropriate tissue is critical because blood may be negative; skin biopsy for fibroblast culture, buccal cells, urine epithelial cells, or affected tissue may be required. Cell-free DNA in maternal plasma can sometimes detect fetal or placental mosaicism.

Germline (Gonadal) Mosaicism

Definition

In germline mosaicism, a pathogenic variant is present in a proportion of germ cells (oocytes or spermatogonia) but absent from somatic cells. The parent is clinically unaffected and tests negative on standard somatic cell testing from blood or saliva. Germline mosaicism is typically discovered when two or more offspring inherit the same apparently "de novo" variant.

Clinical Significance

Germline mosaicism explains the recurrence of apparently de novo dominant conditions in siblings born to unaffected parents. It creates a recurrence risk that is higher than the general population de novo rate but cannot be precisely quantified without direct gonadal sampling. Empiric recurrence risks vary by condition: approximately 7 to 14% for Duchenne muscular dystrophy if the mother tests negative in blood, roughly 7% for osteogenesis imperfecta (COL1A1/COL1A2), about 3% for achondroplasia (FGFR3), 1 to 6% for retinoblastoma (RB1), 1 to 2% for tuberous sclerosis (TSC1/TSC2), and a general empiric estimate of 1 to 5% when no condition-specific data are available.

Gonosomal Mosaicism

Gonosomal mosaicism represents combined somatic and germline mosaicism, where the variant is present at low levels in some somatic tissues as well as in germ cells. This is more common than pure germline mosaicism and may be detectable by deep sequencing of blood, skin, or other accessible tissues. The distinction from pure germline mosaicism is important because gonosomal mosaicism may allow detection through sensitive somatic tissue testing.

Implications for Genetic Counseling

After an apparently de novo event, parents should be counseled about a small but real recurrence risk due to possible germline mosaicism. Prenatal diagnosis should be offered for subsequent pregnancies regardless of negative parental testing. Deep sequencing of parental blood or other tissues can sometimes detect low-level mosaicism and better define recurrence risk. Semen analysis for paternal variants can potentially detect germline mosaicism but is not routinely performed.

Confined Placental Mosaicism (CPM)

Definition

Confined placental mosaicism refers to a chromosomal abnormality present in the placenta (cytotrophoblast and/or mesenchymal core) but absent from the fetus. It affects approximately 1 to 2% of ongoing pregnancies at CVS and arises from post-zygotic errors in cells destined to become extraembryonic tissue.

Types of CPM

Type I involves mosaicism confined to the cytotrophoblast (detected in direct CVS preparation), with the mesenchymal core and fetus being diploid. Type II involves mosaicism only in the mesenchymal core (detected in cultured CVS), with the cytotrophoblast and fetus being diploid. Type III involves mosaicism in both cytotrophoblast and mesenchymal core while the fetus is diploid. Type I is the most common, and Type III carries the greatest clinical significance due to its potential impact on placental function.

Mechanisms

CPM can arise through mitotic error in trophoblast or inner cell mass progenitor cells, generating trisomic or monosomic cells post-zygotically. Alternatively, trisomy rescue occurs when the conception begins as fully trisomic, the placental lineage retains some trisomic cells, and the fetal lineage undergoes "rescue" to disomy, with a 15 to 30% probability of uniparental disomy in the rescued fetal line depending on the chromosome. Monosomy rescue is less common but can result in fetal UPD through duplication of the remaining chromosome.

Clinical Consequences

CPM can cause false-positive prenatal screening results: CVS may show trisomy that is not present in the fetus. Only 10 to 40% of mosaic CVS results represent true fetal mosaicism, and follow-up amniocentesis is indicated when mosaicism is detected on CVS. The trisomy rescue mechanism can result in fetal UPD, which is clinically significant when the chromosome contains imprinted genes. Maternal UPD7 causes Silver-Russell syndrome, paternal UPD11 causes Beckwith-Wiedemann syndrome, maternal UPD14 causes Temple syndrome, maternal UPD15 causes Prader-Willi syndrome, and paternal UPD15 causes Angelman syndrome. CPM involving certain chromosomes, particularly trisomy 16, is associated with adverse pregnancy outcomes including intrauterine growth restriction, preeclampsia, and preterm delivery due to impaired placental function. CPM can also cause false-negative cfDNA screening if placental mosaicism reduces or eliminates the trisomy signal.

Impact on Non-Invasive Prenatal Testing (NIPT/cfDNA)

Cell-free DNA in maternal blood is primarily of placental (trophoblast) origin, not fetal origin. Confined placental mosaicism is the most common biological cause of false-positive NIPT results. Discordance between NIPT and fetal karyotype occurs in approximately 0.1 to 0.4% of cases. All positive NIPT results must be confirmed by diagnostic testing through amniocentesis or CVS.

Revertant Mosaicism

Definition

Revertant mosaicism is the spontaneous correction of a pathogenic variant in a subset of cells, restoring normal gene function. Mechanisms include true back mutation, intragenic recombination, second-site compensatory mutation, and gene conversion.

Clinical Examples

In epidermolysis bullosa, patches of clinically normal skin harbor revertant cells that can potentially be expanded for autologous cell therapy. In Wiskott-Aldrich syndrome, revertant T cells may partially correct the immune deficiency. In Fanconi anemia, somatic reversion in hematopoietic stem cells can lead to improved blood counts. In ichthyosis with confetti, progressive increase in normal skin patches occurs due to revertant mosaicism.

<image>A developmental timing diagram showing how the stage at which a post-zygotic mutation occurs determines the distribution of mosaicism. Starting with a single-cell zygote at the top, branching divisions show: (1) mutation at the 2-cell stage affecting 50% of all tissues, (2) mutation at the 8-cell stage affecting 12.5% of cells, (3) mutation after gastrulation affecting only one germ layer (e.g., ectoderm showing Blaschko lines pattern on a body diagram), and (4) mutation in a tissue progenitor cell affecting only one organ. Each stage shows the resulting body diagram with shaded areas indicating which tissues carry the mosaic variant.</image>

<image>A diagram of confined placental mosaicism (CPM) types. Three panels show cross-sections of a placenta with the cytotrophoblast layer (outer) and mesenchymal core (inner) labeled, alongside the fetus. Type I: trisomic cells (red) only in cytotrophoblast; fetus and mesenchymal core are normal (blue). Type II: trisomic cells only in mesenchymal core. Type III: trisomic cells in both placental layers; fetus is normal. A fourth panel shows the trisomy rescue mechanism: a trisomic conceptus (three copies of a chromosome) undergoes loss of one copy in the fetal lineage, with arrows showing the possibility of UPD if both remaining copies come from the same parent. The connection to false positive NIPT results is indicated with an annotation.</image>

<image>A clinical photography composite showing examples of mosaic conditions distributed along Blaschko lines. A body diagram (anterior and posterior views) shows the characteristic V-shaped pattern on the back, S-shaped curves on the trunk, and linear streaks on the limbs that represent the patterns of ectodermal cell migration during embryogenesis. Annotations identify specific conditions that follow these patterns: hypomelanosis of Ito, linear epidermal nevi, incontinentia pigmenti, and mosaic segmental overgrowth. A key explains that these lines do not follow dermatomal, vascular, or lymphatic distributions.</image>

Clinical Pearls

When a pathogenic variant is detected at an allele fraction significantly below 50% (such as 10 to 30%) on NGS, somatic mosaicism should be considered rather than assuming a germline heterozygous variant with poor sequencing quality. For mosaic overgrowth conditions (PIK3CA, AKT1, GNAQ), genetic testing must be performed on affected tissue such as skin fibroblast from the overgrown region, because blood testing is almost always negative. Pallister-Killian syndrome (mosaic tetrasomy 12p) is virtually never detected on blood karyotype; a skin biopsy for fibroblast culture is the diagnostic standard, though buccal swab or other tissue-based testing may also detect the isochromosome. After an apparently de novo pathogenic variant is found in a child, parents should be counseled that germline mosaicism creates a recurrence risk of approximately 1 to 7% (gene-dependent), and prenatal diagnosis should be offered for future pregnancies. Mosaicism on CVS does not equal mosaicism in the fetus; confirmatory amniocentesis is essential, and UPD testing should be considered for chromosomes with imprinted genes. When NIPT shows a positive result for trisomy, it is important to remember that cfDNA is primarily placental in origin; CPM is the most common cause of NIPT false positives, and diagnostic confirmation is mandatory before any irreversible clinical decisions. Revertant mosaicism is a naturally occurring therapeutic phenomenon that may inform future cell and gene therapy strategies.

References

• Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nat Rev Genet. 2013;14(5):307-320.
• Campbell IM et al. Somatic mosaicism: implications for disease and transmission genetics. Trends Genet. 2015;31(7):382-392.
• Kalousek DK, Vekemans M. Confined placental mosaicism. J Med Genet. 1996;33:529-533.
• Happle R. Mosaicism in Human Skin: Understanding Nevi, Nevoid Skin Disorders, and Cutaneous Neoplasia. Springer. 2014.
• Freed D et al. The contribution of mosaic variants to undiagnosed genetic disease. Genet Med. 2023;25(6):100812.
• Jonkman MF et al. Revertant mosaicism in epidermolysis bullosa. J Clin Invest. 1997;99(10):2345-2349.

Read this lecture as Markdown